Phages in a thermoreversible sustainedrelease formulation targeting E. faecalis in vitro and in vivo

Keyphrases

• Phage 100%
• Sustained Release 100%
• E. Faecalis 100%
• Thermo-reversible 100%
• Viable Bacterial Counts 37%
• Growth Phase 25%
• Scanning Electron Microscopy 25%
• Anti-E 25%
• Phage Treatment 25%
• Root Canal 25%
• Histology 25%
• Antibiofilm 25%
• Poloxamer 407 25%
• Gelation Time 25%
• Microbiota 12%
• Long-lasting Effect 12%
• Clinical Application 12%
• Electron Microscopy 12%
• Genome Sequencing 12%
• Survival Rate 12%
• Healing 12%
• Firmicutes 12%
• Proteobacteria 12%
• Viable Count 12%
• Biofilm 12%
• Conventional Treatment 12%
• Phage Therapy 12%
• Sustained-release Formulation 12%
• Thermo 12%
• Intracanal 12%
• Low Toxicity 12%
• In Vivo Targeting 12%
• Lytic Activity 12%
• Enterococcus Faecalis 12%
• Incisor 12%
• Enterococcus 12%
• Live-dead Staining 12%
• In Vivo Rat Model 12%
• Biofilm Biomass 12%
• Biomass Determination 12%
• Phage Cocktail 12%
• Phage Formulation 12%
• Periapical Inflammation 12%

Immunology and Microbiology

• Bacteriophage 100%
• Biofilm 30%
• Bacterial Count 23%
• Sustained Drug Release 23%
• Infectious Agent 15%
• Colony Forming Unit S 15%
• Scanning Electron Microscopy 15%
• Rhesus E Antibody 15%
• Colony-Forming Unit 15%
• Gelation 15%
• Microflora 7%
• Proteobacteria 7%
• Firmicutes 7%
• Enterococcus faecalis 7%
• Viable Cell Count 7%
• Electron Microscopy 7%
• Rat Model 7%
• Survival Rate 7%
• Incisor 7%
• Genome Sequencing 7%
• Enterococcus 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Bacteriophage 100%
• Sustained Release 23%
• Scanning Electron Microscopy 15%
• Infectious Agent 15%
• Rhesus E Antibody 15%
• Poloxamer 15%
• Electron Microscopy 7%
• Inflammation 7%
• Rat Model 7%
• Enterococcus faecalis 7%
• Survival Rate 7%
• Microflora 7%
• Firmicutes 7%
• Proteobacteria 7%
• Enterococcus 7%